

# Pascal Vranckx

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3126112/publications.pdf>

Version: 2024-02-01

62  
papers

18,258  
citations

147801

31  
h-index

128289

60  
g-index

62  
all docs

62  
docs citations

62  
times ranked

13932  
citing authors

#	ARTICLE	IF	CITATIONS
1	PRECISE-DAPT score for bleeding risk prediction in patients on dual or single antiplatelet regimens: insights from the GLOBAL LEADERS and GLASSY. European Heart Journal - Cardiovascular Pharmacotherapy, 2022, 8, 28-38.	3.0	39
2	Amulet or Watchman Device for Percutaneous Left Atrial Appendage Closure: Primary Results of the SWISS-APERO Randomized Clinical Trial. Circulation, 2022, 145, 724-738.	1.6	61
3	Patients With Atrial Fibrillation and PCI or ACS. Journal of the American College of Cardiology, 2022, 79, 428-431.	2.8	1
4	Ticagrelor Monotherapy or Dual Antiplatelet Therapy After Drug-Eluting Stent Implantation: Per-Protocol Analysis of the GLOBAL LEADERS Trial. Journal of the American Heart Association, 2022, 11, e024291.	3.7	4
5	Ticagrelor monotherapy versus aspirin monotherapy at 12 months after percutaneous coronary intervention: a landmark analysis of the GLOBAL LEADERS trial. EuroIntervention, 2022, 18, e377-e388.	3.2	16
6	Anticoagulation for Percutaneous Ventricular Assist Device-Supported Cardiogenic Shock. Journal of the American College of Cardiology, 2022, 79, 1949-1962.	2.8	36
7	Duration of antiplatelet therapy after complex percutaneous coronary intervention in patients at high bleeding risk: a MASTER DAPT trial sub-analysis. European Heart Journal, 2022, 43, 3100-3114.	2.2	38
8	P2Y12 inhibitor monotherapy in patients undergoing percutaneous coronary intervention. Nature Reviews Cardiology, 2022, 19, 829-844.	13.7	30
9	Safety and efficacy of double vs. triple antithrombotic therapy in patients with atrial fibrillation with or without acute coronary syndrome undergoing percutaneous coronary intervention: a collaborative meta-analysis of non-vitamin K antagonist oral anticoagulant-based randomized clinical trials. European Heart Journal - Cardiovascular Pharmacotherapy, 2021, 7, f50-f60.	3.0	24
10	2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. European Heart Journal, 2021, 42, 1289-1367.	2.2	3,048
11	European Heart Journal “Acute Cardiovascular Care moving onwards and upwards. European Heart Journal: Acute Cardiovascular Care, 2021, 10, 1-2.	1.0	0
12	Predicting 2-year all-cause mortality after contemporary <sc>PCI</sc>: Updating the logistic clinical <sc>SYNTAX</sc> score. Catheterization and Cardiovascular Interventions, 2021, 98, 1287-1297.	1.7	6
13	Comparison of Investigator-Reported and Clinical Event Committee-Adjudicated Outcome Events in GLASSY. Circulation: Cardiovascular Quality and Outcomes, 2021, 14, e006581.	2.2	10
14	Access-Site Crossover in Patients With Acute Coronary Syndrome Undergoing Invasive Management. JACC: Cardiovascular Interventions, 2021, 14, 361-373.	2.9	25
15	Aspirin-free antiplatelet regimens after PCI: insights from the GLOBAL LEADERS trial and beyond. European Heart Journal - Cardiovascular Pharmacotherapy, 2021, 7, 547-556.	3.0	3
16	Design and Rationale of the Swiss-Apero Randomized Clinical Trial: Comparison of Amplatzer Amulet vs Watchman Device in Patients Undergoing Left Atrial Appendage Closure. Journal of Cardiovascular Translational Research, 2021, 14, 930-940.	2.4	7
17	External validation of the GRACE risk score 2.0 in the contemporary all-comers GLOBAL LEADERS trial. Catheterization and Cardiovascular Interventions, 2021, 98, E513-E522.	1.7	1
18	P2Y12 inhibitor monotherapy or dual antiplatelet therapy after coronary revascularisation: individual patient level meta-analysis of randomised controlled trials. BMJ, The, 2021, 373, n1332.	6.0	144

#	ARTICLE	IF	CITATIONS
19	Edoxaban versus Vitamin K Antagonist for Atrial Fibrillation after TAVR. New England Journal of Medicine, 2021, 385, 2150-2160.	27.0	144
20	Dual Antiplatelet Therapy after PCI in Patients at High Bleeding Risk. New England Journal of Medicine, 2021, 385, 1643-1655.	27.0	247
21	Abbreviated Antiplatelet Therapy in Patients at High Bleeding Risk With or Without Oral Anticoagulant Therapy After Coronary Stenting: An Open-Label, Randomized, Controlled Trial. Circulation, 2021, 144, 1196-1211.	1.6	41
22	Efficacy and Safety of Ticagrelor Monotherapy by Clinical Presentation: Pre-specified Analysis of the GLOBAL LEADERS Trial. Journal of the American Heart Association, 2021, 10, e015560.	3.7	18
23	The European Heart Journal Acute Cardiovascular Care (EHJ ACVC) 2022: message from the editorial board. European Heart Journal: Acute Cardiovascular Care, 2021, , .	1.0	0
24	Clinical relevance of ticagrelor monotherapy following 1-month dual antiplatelet therapy after bifurcation percutaneous coronary intervention: Insight from GLOBAL LEADERS trial. Catheterization and Cardiovascular Interventions, 2020, 96, 100-111.	1.7	16
25	Impact of recruitment and retention on all-cause mortality in a large all-comers randomised controlled trial: insights from the GLOBAL LEADERS trial. Clinical Research in Cardiology, 2020, 109, 918-929.	3.3	3
26	Efficacy and safety of one-month DAPT followed by 23-month ticagrelor monotherapy in patients undergoing proximal LAD stenting: Insights from the GLOBAL LEADERS trial. International Journal of Cardiology, 2020, 320, 27-34.	1.7	4
27	Safety and Efficacy of Double Antithrombotic Therapy With Non-Vitamin K Antagonist Oral Anticoagulants in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention: A Systematic Review and Meta-Analysis. Journal of the American Heart Association, 2020, 9, e017212.	3.7	52
28	Edoxaban in atrial fibrillation patients with percutaneous coronary intervention by acute or chronic coronary syndrome presentation: a pre-specified analysis of the ENTRUST-AF PCI trial. European Heart Journal, 2020, 41, 4497-4504.	2.2	20
29	Impact of Bleeding and Myocardial Infarction on Mortality in All-Comer Patients Undergoing Percutaneous Coronary Intervention. Circulation: Cardiovascular Interventions, 2020, 13, e009177.	3.9	15
30	Choice of access site and type of anticoagulant in acute coronary syndromes with advanced Killip class or out-of-hospital cardiac arrest. Revista Espanola De Cardiologia (English Ed ), 2020, 73, 893-901.	0.6	7
31	Cangrelor, Tirofiban, and Chewed or Standard Prasugrel Regimens in Patients With ST-Segment-Elevation Myocardial Infarction. Circulation, 2020, 142, 441-454.	1.6	67
32	DAPT Score and the Impact of Ticagrelor Monotherapy During the Second Year After PCI. JACC: Cardiovascular Interventions, 2020, 13, 634-646.	2.9	17
33	2018 ESC/EACTS Guidelines on myocardial revascularization. European Heart Journal, 2019, 40, 87-165.	2.2	4,537
34	Standardized classification and framework for reporting, interpreting, and analysing medication non-adherence in cardiovascular clinical trials: a consensus report from the Non-adherence Academic Research Consortium (NARC). European Heart Journal, 2019, 40, 2070-2085.	2.2	64
35	Impact of long-term ticagrelor monotherapy following 1-month dual antiplatelet therapy in patients who underwent complex percutaneous coronary intervention: insights from the Global Leaders trial. European Heart Journal, 2019, 40, 2595-2604.	2.2	93
36	Safety and efficacy outcomes of double vs. triple antithrombotic therapy in patients with atrial fibrillation following percutaneous coronary intervention: a systematic review and meta-analysis of non-vitamin K antagonist oral anticoagulant-based randomized clinical trials. European Heart Journal, 2019, 40, 3757-3767.	2.2	211

#	ARTICLE	IF	CITATIONS
37	Ticagrelor Alone Versus Dual Antiplatelet Therapy From 1 Month After Drug-Eluting Coronary Stenting. <i>Journal of the American College of Cardiology</i> , 2019, 74, 2223-2234.	2.8	101
38	Efficacy and Safety of Ticagrelor Monotherapy in Patients Undergoing Multivessel PCI. <i>Journal of the American College of Cardiology</i> , 2019, 74, 2015-2027.	2.8	23
39	Edoxaban-based versus vitamin K antagonist-based antithrombotic regimen after successful coronary stenting in patients with atrial fibrillation (ENTRUST-AF PCI): a randomised, open-label, phase 3b trial. <i>Lancet</i> , The, 2019, 394, 1335-1343.	13.7	465
40	Benefit and Risks of Aspirin in Addition to Ticagrelor in Acute Coronary Syndromes. <i>JAMA Cardiology</i> , 2019, 4, 1092.	6.1	97
41	Association of acute kidney injury and bleeding events with mortality after radial or femoral access in patients with acute coronary syndrome undergoing invasive management: secondary analysis of a randomized clinical trial. <i>European Heart Journal</i> , 2019, 40, 1226-1232.	2.2	26
42	Dyspnoea in the GLOBAL LEADERS trial – Authors' reply. <i>Lancet</i> , The, 2019, 393, 2393-2394.	13.7	3
43	Rationale and design of a prospective substudy of clinical endpoint adjudication processes within an investigator-reported randomised controlled trial in patients with coronary artery disease: the GLOBAL LEADERS Adjudication Sub-Study (GLASSY). <i>BMJ Open</i> , 2019, 9, e026053.	1.9	18
44	Design and rationale of the Management of High Bleeding Risk Patients Post Bioresorbable Polymer Coated Stent Implantation With an Abbreviated Versus Standard DAPT Regimen (MASTER DAPT) Study. <i>American Heart Journal</i> , 2019, 209, 97-105.	2.7	53
45	Impact of angiographic coronary artery disease complexity on ischemic and bleeding risks and on the comparative effectiveness of zotarolimus-eluting vs. bare-metal stents in uncertain drug-eluting stent candidates. <i>International Journal of Cardiology</i> , 2019, 277, 60-65.	1.7	2
46	Patient-oriented composite endpoints and net adverse clinical events with ticagrelor monotherapy following percutaneous coronary intervention: insights from the randomised GLOBAL LEADERS trial. <i>EuroIntervention</i> , 2019, 15, e1090-e1098.	3.2	16
47	Impact of Sex on Comparative Outcomes of Radial Versus Femoral Access in Patients With Acute Coronary Syndromes Undergoing Invasive Management. <i>JACC: Cardiovascular Interventions</i> , 2018, 11, 36-50.	2.9	47
48	2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS. <i>European Heart Journal</i> , 2018, 39, 213-260.	2.2	2,246
49	2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS. <i>European Journal of Cardio-thoracic Surgery</i> , 2018, 53, 34-78.	1.4	261
50	Integrating the results of the CULPRIT-SHOCK trial in the 2017 ESC ST-elevation myocardial infarction guidelines: viewpoint of the task force. <i>European Heart Journal</i> , 2018, 39, 4239-4242.	2.2	25
51	Aspirin-free strategies in cardiovascular disease and cardioembolic stroke prevention. <i>Nature Reviews Cardiology</i> , 2018, 15, 480-496.	13.7	180
52	Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-label, randomised superiority trial. <i>Lancet</i> , The, 2018, 392, 940-949.	13.7	555
53	Standardized End Point Definitions for Coronary Intervention Trials: The Academic Research Consortium-2 Consensus Document. <i>Circulation</i> , 2018, 137, 2635-2650.	1.6	435
54	A Critical Appraisal of Aspirin in Secondary Prevention. <i>Circulation</i> , 2016, 134, 1881-1906.	1.6	70

#	ARTICLE	IF	CITATIONS
55	Is Bare-Metal Stent Implantation Still Justifiable in High Bleeding Risk Patients Undergoing Percutaneous Coronary Intervention?. JACC: Cardiovascular Interventions, 2016, 9, 426-436.	2.9	135
56	Long-term ticagrelor monotherapy versus standard dual antiplatelet therapy followed by aspirin monotherapy in patients undergoing biolimus-eluting stent implantation: rationale and design of the GLOBAL LEADERS trial. EuroIntervention, 2016, 12, 1239-1245.	3.2	92
57	Zotarolimus-Eluting Versus Bare-Metal Stents in Uncertain Drug-Eluting Stent Candidates. Journal of the American College of Cardiology, 2015, 65, 805-815.	2.8	248
58	Does smoking habit affect the randomized comparison of 6 versus 24-month dual antiplatelet therapy duration? Insights from the PRODIGY trial. International Journal of Cardiology, 2015, 190, 242-245.	1.7	5
59	Randomized comparison of Zotarolimus-Eluting Endeavor Sprint versus bare-metal stent implantation in uncertain drug-eluting stent candidates: Rationale, design, and characterization of the patient population for the Zotarolimus-eluting Endeavor Sprint stent in Uncertain DES Candidates study. American Heart Journal, 2013, 166, 831-838.	2.7	18
60	Short- Versus Long-Term Duration of Dual-Antiplatelet Therapy After Coronary Stenting. Circulation, 2012, 125, 2015-2026.	1.6	640
61	A Patient-Level Pooled Analysis Assessing the Impact of the SYNTAX (Synergy Between Percutaneous) Tj ETQq1 1 0.784314 rgBT /Overl Patients Enrolled in Contemporary Coronary Stent Trials. JACC: Cardiovascular Interventions, 2011, 4, 645-653.	2.9	70
62	Standardized Bleeding Definitions for Cardiovascular Clinical Trials. Circulation, 2011, 123, 2736-2747.	1.6	3,378